Dirk‐Thomas Waldschmidt

机构：University of Cologne

发表论文 12 篇 · 总被引 2090 次 · h-index 6

代表论文

• NASH limits anti-tumour surveillance in immunotherapy-treated HCC (2021 · Nature · 被引 1274)
• Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study (2021 · ˜The œLancet. Gastroenterology & hepatology · 被引 433)
• Prognosis of patients with hepatocellular carcinoma treated with immunotherapy – development and validation of the CRAFITY score (2021 · Journal of Hepatology · 被引 309)
• Cabozantinib in Advanced Hepatocellular Carcinoma: Efficacy and Safety Data from an International Multicenter Real-Life Cohort (2021 · Liver Cancer · 被引 41)
• Efficacy, safety and differential outcomes of immune‐chemotherapy with gemcitabine, cisplatin and durvalumab in patients with biliary tract cancers: A multicenter real world cohort (2024 · United European Gastroenterology Journal · 被引 16)
• Evaluation of prognostic scores in patients with HCC undergoing first-line immunotherapy with atezolizumab and bevacizumab (2024 · JHEP Reports · 被引 10)